homepage-top-section

Under the arrangement, the companies will create extended-exposure formulations of selected mRNA candidates from Sanofi by applying ScionxBio’s TERA technology. The partnership divides research and clinical duties between

The capital will fund clinical proof-of-concept testing for the biotechnology company’s lead gene therapy candidates, EST-101 and EST-201, whilst advancing its platform for direct kidney delivery. The total

The initiative centres on creating a high-resolution, patient-derived molecular map of the fatal neurodegenerative disorder, which currently has few effective therapies. Under the terms of the agreement, Mayo

Under the agreement, Alentis has secured an exclusive option to in-license linkers and payloads from PinotBio for use in its pipeline candidates. Financially, PinotBio will receive an upfront

The planned facility will focus on the development, validation, and adoption of new approach methodologies (NAMs). These laboratory, computational, and data-oriented methods are designed to mirror human biology

The transaction grants Ono exclusive development and commercialisation rights for drug candidates BHV-1300, BHV-1310, and BHV-1320 across the Association of Southeast Asian Nations (ASEAN) countries, Taiwan, South Korea,

The renewed arrangement will see Cognizant combine its life sciences sector knowledge with technical services to aid Gilead’s ongoing development and operational processes. The joint work is intended

The 18-storey, 570,000ft² facility at 290 Binney Street features ten floors of interconnecting laboratories equipped with continuous automation, robotics, and agentic AI. Combined with the company’s genomic medicine

The facility will be constructed in the New Albany International Business Park. This investment adds to more than $7bn spent by the company on pharmaceutical research, development, and